MX9701329A - Metodos para la inhibicion de la replicacion viral. - Google Patents

Metodos para la inhibicion de la replicacion viral.

Info

Publication number
MX9701329A
MX9701329A MX9701329A MX9701329A MX9701329A MX 9701329 A MX9701329 A MX 9701329A MX 9701329 A MX9701329 A MX 9701329A MX 9701329 A MX9701329 A MX 9701329A MX 9701329 A MX9701329 A MX 9701329A
Authority
MX
Mexico
Prior art keywords
viral replication
inhibiting viral
methods
hexamethyleneimino
piperidino
Prior art date
Application number
MX9701329A
Other languages
English (en)
Inventor
Andrew Lawrence Glasebrook
David Lynn Phillips
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9701329A publication Critical patent/MX9701329A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un método para la inhibicion de la replicacion viral que comprende la administracion a un humano en la necesidad de éste una cantidad efectiva de un compuesto que tiene la formula (I) en donde R1 y R3 son hidrogeno en forma independiente en donde Ar es en forma opcional fenilo substituido; R2 se selecciona del grupo que consiste de pirrolidino, hexametilenimino, y piperidino; o una sal aceptable en forma farmacéuticamente o solvato de éste.
MX9701329A 1994-08-22 1995-08-21 Metodos para la inhibicion de la replicacion viral. MX9701329A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/294,171 US5494920A (en) 1994-08-22 1994-08-22 Methods of inhibiting viral replication
PCT/US1995/010580 WO1996005830A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting viral replication

Publications (1)

Publication Number Publication Date
MX9701329A true MX9701329A (es) 1997-05-31

Family

ID=23132219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701329A MX9701329A (es) 1994-08-22 1995-08-21 Metodos para la inhibicion de la replicacion viral.

Country Status (15)

Country Link
US (1) US5494920A (es)
EP (1) EP0771200B1 (es)
JP (1) JPH10504572A (es)
AT (1) ATE189601T1 (es)
AU (1) AU3408795A (es)
CA (1) CA2198122A1 (es)
DE (1) DE69515038T2 (es)
DK (1) DK0771200T3 (es)
ES (1) ES2141957T3 (es)
GR (1) GR3033269T3 (es)
IL (1) IL115014A0 (es)
MX (1) MX9701329A (es)
PT (1) PT771200E (es)
WO (1) WO1996005830A1 (es)
ZA (1) ZA956986B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
ATE334394T1 (de) 1995-12-13 2006-08-15 Merck & Co Inc Testverfahren für die sekretionsrezeptoren von wachstumshormonen
CZ300341B6 (cs) 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
ATE477497T1 (de) * 2004-12-08 2010-08-15 Cedars Sinai Medical Center Verfahren zur diagnose von morbus crohn
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100099640A1 (en) * 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
CN112870368A (zh) 2013-03-27 2021-06-01 西达-赛奈医疗中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
PT771200E (pt) 2000-07-31
EP0771200A1 (en) 1997-05-07
JPH10504572A (ja) 1998-05-06
CA2198122A1 (en) 1996-02-29
DE69515038D1 (de) 2000-03-16
IL115014A0 (en) 1995-12-08
WO1996005830A1 (en) 1996-02-29
ATE189601T1 (de) 2000-02-15
ZA956986B (en) 1997-02-21
DE69515038T2 (de) 2000-06-29
ES2141957T3 (es) 2000-04-01
US5494920A (en) 1996-02-27
AU3408795A (en) 1996-03-14
GR3033269T3 (en) 2000-09-29
DK0771200T3 (da) 2000-05-15
EP0771200A4 (en) 1997-09-10
EP0771200B1 (en) 2000-02-09

Similar Documents

Publication Publication Date Title
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
AU7578794A (en) Methods for inhibiting endometriosis
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9706520A (es) Metodos para inhibir el cancer de ovario.